ProQR Therapeutics N.V.
PRQRProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
sepofarsen
Leber Congenital Amaurosis 10
QR-1123
Autosomal Dominant Retinitis Pigmentosa
QR-421a
Retinitis Pigmentosa
QR-010
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sepofarsen | Phase 3 | Leber Congenital Amaurosis 10 | - | - |
QR-1123 | Phase 2 | Autosomal Dominant Retinitis Pigmentosa | - | - |
QR-421a | Phase 2 | Retinitis Pigmentosa | - | - |
QR-010 | Phase 2 | Cystic Fibrosis | - | - |
Frequently asked questions
What is in ProQR Therapeutics N.V.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in ProQR Therapeutics N.V.'s (PRQR) pipeline across Phase 3, Phase 2. Its lead program is sepofarsen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ProQR Therapeutics N.V.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ProQR Therapeutics N.V. (PRQR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRQR biotech catalysts?→
Add PRQR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ProQR Therapeutics N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.